Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Cancer Resectable: early-phase trial registry
3 of 3 indexed Pancreatic Cancer Resectable trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Pancreatic Cancer Resectable: 3 US clinical trials tracked, 3 recruiting.
Pancreatic Cancer Resectable is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is UNC Lineberger Comprehensive Cancer Center, running 1 of these trials.
Enrollment posture brief
Registry condition pancreatic-cancer-resectable
OPEN 3 | RECR 100% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Pancreatic Cancer Resectable lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Cancer Resectable on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Cancer Resectable is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Pancreatic Cancer Detection Consortium
City of Hope Medical Center
NCT06388967
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT06731998
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT03977233
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Cancer Resectable records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Cancer Resectable trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Cancer Resectable page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Pancreatic Cancer Resectable trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- UNC Lineberger Comprehensive Cancer Center sponsors the most Pancreatic Cancer Resectable trials on record, review their full trial history before evaluating a specific study. See UNC Lineberger Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Cancer Resectable condition card totals 3 registered trials; most-linked intervention PANcreatic cancer Exosome Early detectiON (PANXEON); top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.